国家早期预警评分与改良早期预警评分在ACTT新冠队列中的性能分析
研究基于ACTT-1随机对照试验的前瞻性数据,纳入1062例重症COVID-19肺炎成人住院患者,评估NEWS、MEWS及年龄修正版对恢复、机械通气和死亡的预测价值。基线NEWS和MEWS对死亡的c-index为0.60-0.68,加年龄后升至0.66-0.74;对恢复的c-index为0.65-0.69,加年龄后为0.68-0.71;对恶化的c-index为0.59-0.69,加年龄后为0.63-0.70,加年龄的改善均显著(p<0.05)。作者认为这些评分可作为分诊、安置和资源决策的辅助,但不能完全替代临床判断。
要点
- 在1062例重症COVID-19住院成人中,基线NEWS和MEWS对死亡的预测能力弱至中等(c-index 0.60-0.68)。
- 加年龄后NEWS+age和MEWS+age对死亡的预测改善至c-index 0.66-0.74,改善均显著(p<0.05)。
- 对恢复的预测:基线NEWS/MEWS的c-index为0.65-0.69,加年龄后为0.68-0.71。
- 对恶化的预测:基线NEWS/MEWS的c-index为0.59-0.69,加年龄后为0.63-0.70。
- 作者结论:这些评分简单易得,但在COVID-19中预测能力不足以完全替代临床判断,最好作为分诊、安置和资源决策的辅助。
适用人群与场景
- ACTT-1试验纳入的1062例成人非妊娠重症COVID-19肺炎住院患者,来自多中心国际住院试验。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:对ACTT-1随机对照试验前瞻性收集数据的预后评分验证分析,纳入1062例成人非妊娠重症COVID-19肺炎住院患者,多中心国际试验。
- 干预与对照:ACTT-1将参与者随机分配至瑞德西韦组或安慰剂组,预测评分在两组中分别评估以检验瑞德西韦治疗下的差异性能。
- 主要终点结果:对死亡,基线NEWS和MEWS的c-index为0.60-0.68,加年龄后为0.66-0.74;对恢复,基线c-index为0.65-0.69,加年龄后为0.68-0.71;对恶化,基线c-index为0.59-0.69,加年龄后为0.63-0.70;加年龄的改善均显著(p<0.05)。
- 关键次要终点:原文未提及独立于上述终点的其他次要终点结果。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:基于随机对照试验(ACTT-1)前瞻性数据的预后评分验证分析。
- 证据等级或推荐强度:原文未提及。
对床旁实践的改变
- 在重症COVID-19住院成人中,NEWS和MEWS可用于辅助分诊、安置和资源决策,但不应单独用于临床决策。
- 加年龄可显著改善NEWS和MEWS的预测性能(p<0.05),提示在评估时应考虑年龄因素。
- 原文指出这些评分在COVID-19中预测能力不足,不能完全替代临床判断;常见陷阱是过度依赖评分而忽视整体临床评估。
- 原文未提及适用与不适用人群的进一步限定,仅纳入成人非妊娠重症COVID-19肺炎住院患者。
指南或共识出处
- 原文未提及指南或共识名称;研究基于Adaptive COVID-19 Treatment Trial 1队列。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: We sought to validate prognostic scores in coronavirus disease 2019 including National Early Warning Score, Modified Early Warning Score, and age-based modifications, and define their performance characteristics.
DESIGN: We analyzed prospectively collected data from the Adaptive COVID-19 Treatment Trial. National Early Warning Score was collected daily during the trial, Modified Early Warning Score was calculated, and age applied to both scores. We assessed prognostic value for the end points of recovery, mechanical ventilation, and death for score at enrollment, average, and slope of score over the first 48 hours.
SETTING: A multisite international inpatient trial.
PATIENTS: A total of 1,062 adult nonpregnant inpatients with severe coronavirus disease 2019 pneumonia.
INTERVENTIONS: Adaptive COVID-19 Treatment Trial 1 randomized participants to receive remdesivir or placebo. The prognostic value of predictive scores was evaluated in both groups separately to assess for differential performance in the setting of remdesivir treatment.
MEASUREMENTS AND MAIN RESULTS: For mortality, baseline National Early Warning Score and Modified Early Warning Score were weakly to moderately prognostic (c-index, 0.60-0.68), and improved with addition of age (c-index, 0.66-0.74). For recovery, baseline National Early Warning Score and Modified Early Warning Score demonstrated somewhat better prognostic ability (c-index, 0.65-0.69); however, National Early Warning Score+age and Modified Early Warning Score+age further improved performance (c-index, 0.68-0.71). For deterioration, baseline National Early Warning Score and Modified Early Warning Score were weakly to moderately prognostic (c-index, 0.59-0.69) and improved with addition of age (c-index, 0.63-0.70). All prognostic performance improvements due to addition of age were significant (p < 0.05).
CONCLUSIONS: In the Adaptive COVID-19 Treatment Trial 1 cohort, National Early Warning Score and Modified Early Warning Score demonstrated moderate prognostic performance in patients with severe coronavirus disease 2019, with improvement in predictive ability for National Early Warning Score+age and Modified Early Warning Score+age. Area under receiver operating curve for National Early Warning Score and Modified Early Warning Score improved in patients receiving remdesivir versus placebo early in the pandemic for recovery and mortality. Although these scores are simple and readily obtainable in myriad settings, in our data set, they were insufficiently predictive to completely replace clinical judgment in coronavirus disease 2019 and may serve best as an adjunct to triage, disposition, and resourcing decisions.
参考来源
- Colombo CJ, Colombo RE, Maves RC, et al. Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort. Crit Care Explor. 2021. PMID: 34278310. doi:10.1097/CCE.0000000000000474
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。